Trial Profile
A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms DIAMOND
- Sponsors Janssen Pharmaceuticals
- 27 Dec 2019 Results published in the Clinical Infectious Diseases
- 10 Sep 2019 Status changed from active, no longer recruiting to completed.
- 11 Apr 2019 48 week results presented in the Janssen media release.